This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamada, T. Articles by Tanaka, Y. Search for Related Content PubMed PubMed Citation Articles by Yamada, T. Articles by Tanaka, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LEVOTHYROXINE LIOTHYRONINE METHIMAZOLE

An Elevation of Serum Immunoglobulin E Provides a New Aspect of Hyperthyroid Graves’ Disease

Department of Medicine, Kashiwa City Hospital (T.Y., T.N., Y.I., A.T.), Kashiwa, Chiba 277; Department of Medicine, Dokkyo Koshigaya Hospital, Dokkyo University School of Medicine (A.S.), Koshigaya, Saitama 343-8555; Second Department of Medicine, Faculty of Medicine, University of the Ryukyus (I.K.), Nishihara, Okinawa 903-0215; and First Department of Medicine, University of Occupational and Environmental Health (S.E., Y.T.), Yawatanishiku, Kitakyushu 807-8555, Japan

Address all correspondence and requests for reprints to: Akira Sato, M.D., Department of Medicine, Dokkyo Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya, Saitama 343-8555, Japan. E-mail: asato{at}dokkyomed.ac.jp

In hyperthyroid Graves’ disease, short-term methimazole is sufficient to induce lasting remission in some patients, but even long-term treatment fails to do so in others. We have evaluated the role of autoimmune abnormalities in the helper T cell type 2 (TH2)-interleukin-13 (IL-13)-TSH receptor system in maintaining hyperthyroidism by comparing IgE levels in patients with various thyroid diseases.

One hundred and ninety-three patients with hyperthyroid Graves’ disease were treated with methimazole, and blood samples were obtained to measure serum levels of T₄, T₃, TSH, thyroglobulin, antimicrosomal antibody, TSH binding inhibitory Ig (TBII), thyroid-stimulating antibody, thyroid stimulation-blocking antibody, IgE, interferon-, IL-4, and IL-13. Elevation of serum IgE (170 U/mL) was found in 35.5% of patients with hyperthyroid Graves’ disease, and serum levels of T₄, T₃, antimicrosomal antibody, and TBII were significantly greater in patients with IgE elevation than in those with normal serum IgE. During methimazole treatment, there was a parallel decrease in the serum T₄ concentration in the presence or absence of an IgE elevation. However, there was a significantly smaller decrease in TBII in patients with elevated IgE than in those with normal IgE. As a result, the remission rate was significantly greater in patients with normal IgE than in those with IgE elevation. Serum levels of IL-13 were elevated in 64.7% of patients with IgE elevation in the absence of detectable TH1 marker, interferon-.

These findings suggest that in one third of patients with hyperthyroid Graves’ disease, TH2 cells are stimulated and secrete excess amounts of IL-13, which subsequently stimulates B cells to synthesize more TSH receptor antibody and IgE, so that during methimazole treatment TBII decreases less in patients with IgE elevation, producing a lower remission rate.

This article has been cited by other articles:

				Y. Hiromatsu, T. Fukutani, M. Ichimura, T. Mukai, H. Kaku, H. Nakayama, I. Miyake, S. Shoji, Y. Koda, and T. Bednarczuk Interleukin-13 Gene Polymorphisms Confer the Susceptibility of Japanese Populations to Graves' Disease J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 296 - 301. [Abstract] [Full Text] [PDF]

				C.-R. Chen, H. Aliesky, P. N. Pichurin, Y. Nagayama, S. M. McLachlan, and B. Rapoport Susceptibility Rather than Resistance to Hyperthyroidism Is Dominant in a Thyrotropin Receptor Adenovirus-Induced Animal Model of Graves' Disease as Revealed by BALB/c-C57BL/6 Hybrid Mice Endocrinology, November 1, 2004; 145(11): 4927 - 4933. [Abstract] [Full Text] [PDF]

				Y. Nagayama, H. Mizuguchi, T. Hayakawa, M. Niwa, S. M. McLachlan, and B. Rapoport Prevention of Autoantibody-Mediated Graves'-Like Hyperthyroidism in Mice with IL-4, a Th2 Cytokine J. Immunol., April 1, 2003; 170(7): 3522 - 3527. [Abstract] [Full Text] [PDF]

				O M P JOLOBE Thyroid disorders{---}an update Postgrad. Med. J., February 1, 2001; 77(904): 144 - 144. [Full Text]